Deuterated colexitinib (decavatinib) medical insurance reimbursement ratio and patient out-of-pocket amount

Deuterated colexitinib (decavatinib) has been officially launched in China and has been included in the national medical insurance reimbursement catalog, which provides protection for patients to reduce their financial burden. The common domestic specifications are 6mg*7 tablets, and the latest price per box is about more than 1,000 yuan. After being included in medical insurance, patients can enjoy a certain proportion of reimbursement according to local medical insurance policies if they meet the reimbursement conditions, thereby reducing actual out-of-pocket expenses.

The reimbursement ratio of medical insurance varies from region to region. Generally, patients with medical insurance can reimburse about 50% to 70% of the cost of drugs, which means that the actual amount patients pay for each box of drugs may be around 300 to 500 yuan. The specific reimbursement amount will be affected by factors such as the type of medical insurance (urban employee medical insurance, urban and rural residents medical insurance), reimbursement threshold and annual cap line. Therefore, patients should confirm the specific local policies with their hospital or pharmacy before purchasing drugs.

For patients who require larger doses or long-term treatment, the overall treatment cost can be reduced through medical insurance reimbursement, but they still need to pay part of the cost out of pocket. Compared with foreign markets, the original version of deuterated colexitinib 6mg*30 tablets in the United States sells for about 50,000 yuan, while the regular generic version in Laos and Bangladesh costs about 400 to 500 yuan per box, which shows the important role of domestic medical insurance reimbursement in reducing patients' financial pressure. When patients choose medicines, they can reasonably choose specifications and purchase channels based on medical insurance policies and their own economic conditions.

Taken together, domestic deuterated coxitinib has achieved effective control of patient costs by being included in medical insurance. Although the reimbursement ratio varies by region and type of medical insurance, under the coverage of medical insurance, the patient's out-of-pocket amount is significantly reduced, especially for patients with psoriasis or other indications who require long-term maintenance treatment, which helps ensure the continuity and compliance of treatment. At the same time, patients should understand the medical insurance policy and reimbursement process in detail before purchasing drugs in order to maximize the use of medical insurance resources and reduce the financial burden.

Reference materials:https://www.drugs.com/